课题基金 / 基金详情

5-FU AND RINF-2 ALPHA IN PATIENTS WITH ADVANCED COLORECTAL CANCER

5-FU AND RINF-2 ALPHA IN PATIENTS WITH ADVANCED COLORECTAL CANCER
5-FU 和 RINF-2 ALPHA 在晚期结直肠癌患者中的应用
批准号：
3863991
负责人：
RONALD BLUM
金额：
$0.0万
依托单位：
NEW YORK UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3863991
关键词：
clinical trials colorectal neoplasms combination chemotherapy drug administration rate /duration drug adverse effect fluorouracil human subject human therapy evaluation interferons neoplasm /cancer chemotherapy

项目摘要

项目成果

RONALD BLUM的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The object of this study is to examine the response rate of the combination of 5-Fluorouracil (5-FU) administered as a loading course followed by weekly bolus therapy, in combination with rIFN-2a given subcutaneously 3 times per week; to determine the toxicity and reversibility of toxicities, duration of survival and duration of response to this treatment on colorectal carcinoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ECOG C9344 DOXORUBICIN DOSE ESCALATION +/- TAXOL FOR NODE POSITIVE BREAST CANCER
SWOG 94-20 CORRELATION OF THYMIDYLATE SYNTHASE IN 5 FU TREATED COLORECTAL CANCER
ECOG S9313--ADJUVANT CHEMOTHERAPY IN HIGH RISK BREAST CANCER PATIENTS
ECOG 91140--CDP, DTIC, CARMUSTINE & TAMOXIFEN VS DTIC IN ADVANCED MELANOMA
海外基金